BioSpace News Archive

FDA

FDA Approves UTILITY’s New Antibiotic for Uncomplicated UTI in Women

The regulator on Wednesday gave its approval for a new oral antibiotic to treat uncomplicated urinary tract infections in women. UTILITY therapeutics expects to launch Pivya in the U.S. in 2025.

April 25, 2024
·
2 min read
·
Tristan Manalac
Business

BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1

Bristol Myers Squibb announced Thursday it is implementing major cost-cutting measures including thinning out its management layers. The pharma also reported modest revenue growth despite taking a 6% sales hit for lung cancer therapy Opdivo.

April 25, 2024
·
2 min read
·
Tristan Manalac
Business

Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20%

Merck’s bestselling immunotherapy raked in $6.9 billion in the first quarter of 2024. Analysts had been expecting $6.71 billion in Keytruda sales, according to estimates from FactSet.

April 25, 2024
·
2 min read
·
Kate Goodwin
Policy

Sanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy

Sen. Bernie Sanders (I-Vt.) on Wednesday launched an investigation into the exorbitant prices of Novo Nordisk’s Ozempic and Wegovy blockbusters, and has asked the Danish drugmaker to justify their price tags.

April 25, 2024
·
2 min read
·
Tristan Manalac
Business

Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery

Regeneron will use Mammoth Biosciences’ tiny Cas enzymes to deliver in vivo CRISPR-based gene editing therapies to tissues and cell types beyond the liver, the companies announced Thursday.

April 25, 2024
·
2 min read
·
Nick Paul Taylor
Business

Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1

Sanofi is dropping its Sjögren’s syndrome candidate due to disappointing Phase II efficacy data, while AstraZeneca is stopping work on some early-stage assets amid a portfolio reprioritization.

April 25, 2024
·
2 min read
·
Tyler Patchen
Drug Development

As Autism Cases Rise, Biopharma Springs Into Action

Several companies—including Roche, Curemark and Yamo Pharmaceuticals—are running clinical trials of treatments that aim to offset the myriad challenges of autism.

April 25, 2024
·
6 min read
·
Tyler Patchen
Opinion: Can Ketamine Be Safely Used at Home?

Ketabon is working to develop a medication that harnesses ketamine’s antidepressant effects without the safety issues that currently prohibit its at-home use.

April 25, 2024
·
7 min read
·
Hans Eriksson
Cybin to Participate at the 27th Annual Milken Institute Global Conference

Cybin Inc. today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled “Collaborating for Improved Mental Health.”

April 25, 2024
·
6 min read
Business

Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024

Achieve Life Sciences, Inc. (Nasdaq: ACHV) today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT.

April 25, 2024
·
4 min read